Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
96 hedge funds and large institutions have $830M invested in Tetraphase Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 37 increasing their positions, 18 reducing their positions, and 11 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
218% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 11
191% more capital invested
Capital invested by funds: $285M → $830M (+$545M)
106% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 18
32% more funds holding
Funds holding: 73 → 96 (+23)
27% less call options, than puts
Call options by funds: $3.67M | Put options by funds: $4.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$35M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$27.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23M |
| 5 |
IG
ING Group
Amsterdam,
Netherlands
|
+$21.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$19.1M |
| 2 |
DM
Deerfield Management
New York
|
-$8.98M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$8.88M |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
-$4.86M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$3M |
TTPH Hedge Fund Activity: Q4 2014 in Review
96 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2014, worth a combined $830M — up 191% from $285M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new TTPH positions and 11 closed out — a net gain of 24 holders — while 37 added to existing stakes and 18 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $35M. The largest seller was Broadfin Capital, exiting entirely with an estimated $19.1M sold.
- 96 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2014, up from 73 in Q3 2014.
- Funds reported $830M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2014, up 191% quarter-over-quarter.
- 35 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2014 and 11 closed out, a net change of +24 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2014 was BB Biotech, an estimated $35M added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2014 was Broadfin Capital, an estimated $19.1M sold.
Based on aggregated 13F filings for Q4 2014.